According to the Alzheimer’s Association, approximately 5.2 million Americans are living with Alzheimer’s. Someone develops Alzheimer’s every 71 seconds, and it is the sixth-leading cause of death. To fight the mental, physical and emotional devastation this disease causes individuals, family and friends, Memory Pharmaceuticals Corp. (Nasdaq: MEMY) is focused on developing innovative drugs for the treatment of debilitating CNS disorders that may impair memory and other cognitive functions, including Alzheimer’s disease and schizophrenia.
The company today announced the completion of its phase I multiple ascending dose study of R4996/MEM 63908. The study is the fourth and final study involving health volunteers to determine the efficacy of the nicotinic alpha-7 receptor being developed in collaboration with Roche.
Per the agreement, Memory Pharmaceuticals is responsible for conducting the clinical trials, while Roche is responsible for later-stage development and commercialization.
“We conducted a robust and comprehensive phase 1 program for R4996/MEM 63908, during which
...